SCHEMBL5227878

SCHEMBL5227878

COc1cc(NC(=O)N2CCOCC2)ccc1-c1nc2c(c(-c3ccccc3)nn2C)c(=O)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 3/20 0.43
PDE7A Q13946 2/20 0.42
PDE5A O76074 7/20 0.42
ROS1 P08922 1/20 0.42
ALK Q9UM73 1/20 0.42
HTR1A P08908 2/20 0.40
HTR1D P28221 2/20 0.40
HTR1B P28222 2/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR6 P50406 1/20 0.40
BLM P54132 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
PTPN7 P35236 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5231866 0.87 PDE5A (0.45) ALDH1A1PDE7APDE5AKDM4EMAPK1
SCHEMBL5228648 0.86 PDE5A (0.53) PDE7APDE5A
SCHEMBL5233971 0.85 PDE5A (0.54) PDE7APDE5AKDM4E
SCHEMBL5227871 0.83 PDE7A (0.64) SMN1; SMN2PDE7A
SCHEMBL5267205 0.83 PDE5A (0.46) PDE7APDE5ACYP2C19
SCHEMBL5233839 0.83 PDE7A (0.46) PDE7APDE5A
SCHEMBL5233533 0.83 BRD4 (0.53) PDE7APDE5A
SCHEMBL5228324 0.83 PDE7A (0.48) PDE7APDE5AKDM4E
SCHEMBL5236848 0.81 PDE5A (0.44) PDE7APDE5A
SCHEMBL5228488 0.80 MAPT (0.47) SMN1; SMN2ALDH1A1PDE7APDE5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A SMN1; SMN2 4062/4885ALDH1A1 711/4885PDE7A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.